Difference between revisions of "2017-Aug-11 BiWeekly PhUSE Nonclinical ADA Endpoint Modeling"

From PHUSE Wiki
Jump to: navigation, search
Line 36: Line 36:
| Rihab Kordane || X
| Rihab Kordane || X
| Stephen MacMannis ||  
| Stephen MacMannis || X
| Trina Jiao ||  
| Trina Jiao ||  

Revision as of 08:08, 11 August 2017

<< Go back to the Investigating Endpoint Modeling - ADA Minutes Page When: 2017-08-11, 09:00-10:00 EDT
Place: Telecon



Participant Attended
Mike Wasko X
Gretchen Dean X
Thomas Bjerregaard X
Alan Brown
Christy Kubin
Janessa Pierce
Jennifer Emeneggee
Joleen White X
Joyce Ford
Kennan Marsh
Leslie Lorello X
Rihab Kordane X
Stephen MacMannis X
Trina Jiao
Wendy Freeburn X
William Houser X
Susan Steen X
Anna Pron-Zwick X
Dennis Stocker X
Jordan Li X


Next meeting: Aug 25, 2017 at 09:00 to 10:00 EDT

Meetings: 2 week schedule


1) Introductions

2) Usage of PhUSE Wiki: http://www.phusewiki.org/wiki/index.php?title=Modeling_Endpoints:_How_to_Model_Anti-Drug_Antibody_Data_in_Nonclinical_Studies

3) Reviewed charter

4) Discussions: Mike shared feedback received from PhUSE Steering Committee was to make sure we are not introducing new/conflicting methodology as to what clinical is doing. Can we model using existing domains in SEND 3.0?

Bill Question: Is there someone from clinical team that could join?

Thomas shared Novo Nordisk approach: shared usage of LB domain which was rejected by CDISC as terminology to be used in the LB code list and recommended it be used in IS. IS domain is used in clinical – where they intend to use as measurement for immunogenicity. Problem is IS domain is not available in SEND 3.0. ADA is compound specific and generic terms need to work together. Concern about hijacking the subcat used in clinical.

ADA reporting: positive/negative result as well as titer or RLU (e.g., magnitude of response)

Company to company variability in how assay methodology is applied (screen vs titre), neutralizing and cross reactivity, so needs to be flexible. Some companies may do binding and neutralizing. Methods can also be developed for cross reactivity (e.g. against administered compound and endogenous target).

Remit: guidance on SEND and future implementations and address how we should approach under SEND3.0.

FDA won’t expect dataset in standardized format until standard is defined and pilots have been conducted.


Types of expertise on the team:

Scientific representation – Nonclinical. Can we add someone from Clinical?

CDISC Controlled terminology team (Virology) – Jordan Li

SDTM IS representation – Craig ?

FDA rep -for expectations in nonclinical

Action Items

Responsible Task Timeframe
Mike Update Wiki Next few days
Group Each member to track down an example of data set used in submission for clinical (SDTM). Will likely need to reach out to clinical data management function within your organization (target 1 month) By next meeting
Group Future meeting – share example of anonymized/mock data (Leslie and Thomas – 8/11 & 25) Can be shared in excel format. By next meeting

Last revision by Mwasko79, 2017-08-11